Emirates Pharma adopts Itakamah for ESR1 breast cancer
The UAE Federal Authority for Medicines has announced the approval of the drug "Etkamah" from AstraZeneca. It is the first oral treatment available in the UAE for patients with advanced or metastatic breast cancer who have a mutation in the ESR1 gene following hormonal therapy. The medication is based on the active ingredient camizestrant and is used in combination with CDK4/6 inhibitors. Its goal is to block estrogen receptors and improve patient outcomes, based on a comprehensive evaluation that demonstrated its effectiveness in a recent clinical study. This development marks a significant step forward in providing advanced treatment options and establishing the UAE as a leading destination for pharmaceutical innovation.
Notice: This Is an AI-Generated Summary
Comments (0)